PDF herunterladen
Int J Angiol 2013; 22(01): 049-054
DOI: 10.1055/s-0033-1334093
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein

Anwar Santoso
1   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Harapan Kita Hospital, National Cardiovascular Centre, Jakarta, Indonesia
,
Marita Kaniawati
2   School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
,
Syakib Bakri
3   Department of Internal Medicine, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
,
Irawan Yusuf
4   Department of Physiology, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Februar 2013 (online)

    Lizenzen und Reprints

Abstract

In coronary heart disease (CHD), levels of secretory phospholipase A2 (sPLA2) are commonly increased. Serum amyloid-A (SAA) is increased in acute coronary syndromes (ACS) as well. It is needed to verify the hypotheses that sPLA2 is associated with the odds of ACS through elevation of SAA. We conducted a case–control study with 57 male patients with ACS and 30 controls matched by gender category. Levels of sPLA2, SAA, and myeloperoxidase (MPO) were measured by immunoreactive assay on the basis of a double-antibody sandwich technique. Levels of sPLA2, MPO, and SAA were significantly higher in patients than those in controls (11,359.0 ± 10,372.4 pg/mL vs. 1,320.5 ± 654.5 pg/mL, p = 0.00; 438.6 ± 310.7 ng/mL vs. 271.1 ± 176.8 ng/mL, p = 0.01; 10,995.2 ± 2,842.6 ng/mL vs. 3,861.7 ± 3,173.5 ng/mL, p = 0.00). There were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00). On multivariate logistic regression analyses, there were significant and independent associations between sPLA2 and SAA with odds of ACS [OR (95% CI) = 14.2 (2.1 to 98.6), p = 0.00; OR (95% CI) = 44.9 (6.9 to 328.4), p = 0.00]. Our findings suggest that sPLA2 may be associated with the odds of ACS compared with controls through increased inflammation, represented by elevated SAA.

Keywords

acute coronary syndromes - secretory phospholipase A2 - myeloperoxidase - serum amyloid-A - coronary heart disease - case–control study - odds ratio
 

  • References

  • 1 Kugiyama K, Ota Y, Takazoe K , et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999; 100 (12) 1280-1284
    CrossrefPubMedGoogle Scholar
  • 2 Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009; 30 (22) 2742-2748
    CrossrefPubMedGoogle Scholar
  • 3 Mallat Z, Steg PG, Benessiano J , et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005; 46 (7) 1249-1257
    CrossrefPubMedGoogle Scholar
  • 4 Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994; 269 (18) 13057-13060
    PubMedGoogle Scholar
  • 5 Hurt-Camejo E, Camejo G, Peilot H, Oörni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001; 89 (4) 298-304
    CrossrefPubMedGoogle Scholar
  • 6 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340 (6) 448-454
    CrossrefPubMedGoogle Scholar
  • 7 Bassand JP, Hamm CW, Ardissino D , et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28 (13) 1598-1660
    CrossrefPubMedGoogle Scholar
  • 8 Van de Werf F, Bax J, Betriu A , et al. Management of acute myocardial infarction in patient presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945
    CrossrefPubMedGoogle Scholar
  • 9 Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A2 in human monocyte derived macrophages. Arterioscler Thromb Vasc Biol 2000; 20: 1276-1282
    CrossrefPubMedGoogle Scholar
  • 10 Kugiyama K, Ota Y, Sugiyama S , et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000; 86: 718-722
    CrossrefPubMedGoogle Scholar
  • 11 Van Lenten BJ, Hama SY, de Beer FC , et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96 (6) 2758-2767
    CrossrefPubMedGoogle Scholar
  • 12 Morrow D, Rifai N, Antman E , et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 2000; 35: 358-362
    CrossrefPubMedGoogle Scholar
  • 13 Johnson BD, Kip KE, Marroquin OC , et al. Serum amyloid A as a predictor of coronary heart disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732
    CrossrefPubMedGoogle Scholar
  • 14 Brennan ML, Penn MS, Van Lente F , et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349 (17) 1595-1604
    CrossrefPubMedGoogle Scholar
  • 15 Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30 (2) 151-155
    CrossrefPubMedGoogle Scholar